In focus
Latest feed
EyePoint's Wild Ride: A Failed Trial, Massive Losses, and a Glimmer of Hope
EyePoint's Rollercoaster Week: A Glimmer of Hope Amidst Trial Setbacks and Downgrades
Regeneron Pharmaceuticals (REGN) Shareholder Call: Numbers, Pipeline, and What’s Next
Nasdaq's Remarkable Reversal: How Chipmakers Sparked a Green Comeback
